Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gene therapy using herpes simplex virus-based vectors.

D S Latchman1

  • 1Institute of Child Health, University College London, UK. d.latchman@ich.ucl.ac.uk

Histology and Histopathology
|September 27, 2000
PubMed
Summary

Gene therapy uses genes to treat diseases, with herpes simplex virus (HSV) showing promise for neurological conditions due to its large genome and ability to enter a latent state in neurons.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Proliferation-associated Brn-3b transcription factor can activate cyclin D1 expression in neuroblastoma and breast cancer cells.

Oncogene·2023
Same author

STAT1 deficiency in the heart protects against myocardial infarction by enhancing autophagy.

Journal of cellular and molecular medicine·2011
Same author

Herpes simplex virus life cycle and the design of viral vectors.

Methods in molecular biology (Clifton, N.J.)·2011
Same author

Growth of herpes simplex virus and purification of viral DNA.

Methods in molecular biology (Clifton, N.J.)·2011
Same author

HSV-Cellular Protein Interactions.

Methods in molecular medicine·2011
Same author

EWS/ETS proteins promote expression and regulate function of the homeodomain transcription factor BRN3A.

Oncogene·2010

Area of Science:

  • * Molecular biology
  • * Virology
  • * Neuroscience

Background:

  • * Gene therapy requires efficient gene delivery systems.
  • * Herpes simplex virus (HSV) offers unique advantages for gene delivery, particularly in the nervous system.
  • * HSV's large genome and neuronal latency are key features for therapeutic applications.

Purpose of the Study:

  • * To evaluate the potential of herpes simplex virus (HSV) as a gene delivery system for human gene therapy.
  • * To highlight HSV's advantages, including its large genome size and ability to establish latency in neuronal cells.
  • * To discuss the progress and challenges in developing disabled HSV for treating neurological diseases.

Main Methods:

  • * Development of disabled herpes simplex virus (HSV) vectors.
  • * Assessment of HSV's gene delivery efficiency and long-term foreign gene expression.
  • * Testing of HSV vectors in preclinical models of human diseases (rodent and primate).

Main Results:

  • * Significant progress in disabling HSV while maintaining its gene delivery capabilities.
  • * Demonstrated potential for long-term expression of foreign genes using modified HSV.
  • * Identified ongoing challenges in viral disablement and comprehensive preclinical testing.

Conclusions:

  • * Disabled HSV vectors show considerable promise for gene therapy, especially for intractable neurological disorders.
  • * Further disablement and extensive testing in animal models are necessary before human application.
  • * HSV-based gene therapy holds potential for treating otherwise untreatable neurological diseases.

Related Experiment Videos